Targeting vehicle

Charges should be a minimum of 20 pounds of TNT or its equivalent if the charge is directly under the road surface, increasing by 20 pounds per foot of depth. If the target vehicle is armored, double the charge. 

The toxins mentioned above have the disadvantage as targeting vehicles that they can only be used on toxin-resistant cells as they will kill normal cells. It is possible to make mutant toxins with highly reduced toxicity, but so far such mutants have proved to be less active in translocation than the wild-type toxins. In future work it may therefore be necessary to look for other toxins that do not kill the cells. 

Market determination Vehicle performance targets Vehicle mass targets8... 

ACC differs from other vehicle control functions, especially in that the function is performed by several electronic control units (ECUs). While conventional control systems consist of a sensor and actuator environment around a central ECU, ACC adds functions to existing systems. A truly new component is the sensor for measuring the distance, relative speed, and lateral position of potential target vehicles, using laser optics or millimeter waves. This component often contains the logic for controlling vehicle movement. The latter is affected by commands of ECUs for engine and brake control electronics. 

Biopharmaceuticals as Targeting Vehicles for In situ Radiotherapy of Malignancies... 

The gastrointestinal toxicity observed in patients receiving pre-targeted RIT was speculated to be due to cross-reactivity of the NR-LU-10 mAb with normal bowel, and not because of hepatobiliary excretion of °Y-DOTA-biotin. Cross-reactivity of NR-LU-10 with renal tubules was similarly thought to explain the increase in serum creatinine in two patients. The authors of the study concluded that pre-targeted RIT of malignancies in patients was feasible, but that the NR-LU-10 mAh was not an appropriate pre-targeting vehicle, due to its unfavorable normal tissue cross-reactivity. 

Peptides offer an attractive alternative to mAbs as targeting vehicles for in situ radiotherapy of cancer, since their much lower molecular weight (Mj 1-6 kDa) results in rapid ehmination from the blood by renal excretion, and facilitates their penetration into solid tumors [24]. The decreased residence time of radioactivity in the blood diminishes bone marrow toxicity and permits dose escalation to potentially therapeutic levels. Peptide-directed radiotherapy (PDRT) of cancer has focused mainly on treatment of malignancies expressing somatostatin receptors (SSR) with Y-DOTA-D-Phe -Tyr -octreotide ( °Y-DO-TATOC), a synthetic octapeptide analogue of somatostatin [79, 80]. However, many endogenous growth factors are peptides. 

The application of biomolecules as targeting vehicles for in situ radiotherapy of malignancies, although now conceptually more than 20 years old, is stiU rapidly... 

---